BRD9 and mesothelioma: We indicated that elevated BRD9 expression was linked to an adverse prognosis, with regards to OS, for adrenocortical carcinoma (ACC), LIHC, mesothelioma (MESO) and sarcoma (SARC) cohorts (Figure 3A).